# SEG P0 Evidence Closure Progress Report

**Document ID:** `SEG_P0_EVIDENCE_CLOSURE_PROGRESS_REPORT`  
**Mode:** `CONTROLLED CONTENT GOVERNANCE EXECUTION`  
**Review pathway:** `OWNER_GOVERNED_MEDICAL_REVIEW_PATHWAY`  
**Targets:** Drug HTML, OSCE Atlas, and PreTest  
**Execution timestamp:** `2026-08-22T15:12:09+00:00` — observed evidence-closure execution timestamp

## 1. Executive determination

This batch completed the available evidence-closure documentation actions for the three P0 assets. It locked and restated evidence already supported by retained artifacts, defined the remaining closure requirements, and prepared the next owner-governed review steps. It did not invent external evidence, appoint or invent reviewers, modify source content, or grant approval.

The resulting state is:

```text
APPROVED_SOURCES = NONE
NORMALIZATION = BLOCKED_PENDING_APPROVED_SOURCE
SOURCE_REGISTRY_APPROVAL_STATES = UNCHANGED
```

No source qualifies for `READY_FOR_NORMALIZATION`.

## 2. Source-by-source progress

| Source | Evidence closed or documented | Evidence remaining | Review remaining | Current gate | Next action |
|---|---|---|---|---|---|
| Drug HTML | Retained artifact identity/path/size/line count/SHA-256; internal metadata definition; structural field inventory; internal retained-representation version ID `SEG-P0-DRUG-HTML-LOCAL-INTAKE-001`; clinical-field and safety-review requirements | Canonical source/title/owner/version/date/locator; provenance/extraction lineage; rights/display scope; track/taxonomy; entity-level clinical field evidence | Owner-governed Emergency Medicine, Pharmacology/Drug Safety, metadata, technical HTML/lineage, rights/provenance, and audit review | `BLOCKED_PENDING_EVIDENCE` | Assemble source/version/rights/provenance packet and execute separate reviews against the locked HTML hash |
| OSCE Atlas | Package identity, inner/outer hashes, archive integrity, 14-PNG inventory and per-file hashes, technical dimensions/encoding, per-image labeling/accessibility requirements | Canonical atlas/source/owner/version/date/locator; per-image source lineage; transformation history; per-image rights/display scope; complete station mapping | Owner-governed Emergency Medicine/OSCE, Visual, Accessibility, technical, rights/provenance, and audit review for all 14 members | `BLOCKED_PENDING_EVIDENCE` | Preserve package unchanged, reconcile all 14 members, obtain authoritative/custodian evidence, and execute per-image review streams |
| PreTest | Retained `UPD811-007` identity/path/size/line count/SHA-256; known OCR issue register; reconciliation checklist; question-inventory requirements; answer/explanation validation requirements | Authoritative `pretestnew.pdf` or equivalent; canonical source/title/owner/version/date/locator; OCR comparison; completeness/numbering baseline; answer-key and explanation inventory; provenance/rights | Owner-governed Emergency Medicine, Assessment Quality, technical/OCR, metadata, rights/provenance, and audit review | `BLOCKED_PENDING_EVIDENCE` | Recover authoritative representation, preserve both artifacts, perform read-only source-to-text/OCR reconciliation, then execute review streams |

The word **closed** in this report refers only to an evidence or requirement documentation item. It does not mean that the source-level governance gate, review gate, rights gate, or approval gate is closed.

## 3. Drug HTML progress

The retained artifact is `LOCAL_INTAKE_ARTIFACT` at `/home/ubuntu/upload/deepseek_html_20260615_a3266b.html`, with 25,918 bytes, 394 lines, and SHA-256 `5367711d08df2393cf852815b1b9d0ad4dac8240ac061cd88c71a53884e938ac`. The structural inventory records 19 `summaryData` sections, 21 `quick` entries, 47 `drugList` entities, and 20 `trapsList` entries. These observations are structurally confirmed and do not establish clinical correctness or drug safety.[1]

The internal metadata definition is documented, including the governance-only retained-representation version `SEG-P0-DRUG-HTML-LOCAL-INTAKE-001`. The definition does not replace a canonical source version or publication date. Clinical field requirements are recorded as `NOT_ESTABLISHED` until an attributable review examines each relevant entity and section.

Canonical source identity, publisher/custodian, version/date, original locator, extraction/transformation history, rights, track/taxonomy, clinical field evidence, drug-safety findings, metadata disposition, technical review, and attributable owner-governed review records remain open. The next allowed action is controlled evidence acquisition and separate review execution only.

## 4. OSCE Atlas progress

The locked target is `ATLAS_ASSET_OSCE_VISUAL_001`. The inner package SHA-256 is `ca5a7f5713bf5101daa839a546633366d7b5b876604bd3dbf7cea2972d59f66e`, and the outer recovery-container SHA-256 is `8182d243fc762e29efba5adeda4233042f5e337846b3fbe819fcd374ef948758`. Archive integrity and the 14-PNG package inventory are confirmed. The per-image table records all 14 exact identifiers and hashes, and defines the clinical-label and accessibility requirements for each member.[2]

The evidence remains package/member continuity evidence only. The current package does not establish canonical atlas identity, creator/owner, edition/version/date, original locator, per-image source lineage, transformation history, rights, complete station mapping, clinical relevance, labeling accuracy, visual quality, or accessibility. The two readability notes for `016_first_degree_heart_block.png` and `142_acute_cholecystitis.png` remain limited observations and cannot be generalized to the other 12 members.

The next allowed action is to preserve the package and members unchanged, reconcile the complete 14-member list with authoritative source/custodian evidence, and execute separate owner-governed clinical/educational, visual, accessibility, technical, rights, provenance, and audit reviews. The PNG set remains separate from the Clinical Images source family.

## 5. PreTest progress

The locked representation is `UPD811-007`, `/home/ubuntu/seg-manus-status/phase_7_8_10_updated_source_intake/كتب علاء نص دراسي/pretestnew_Study_Guide_UTF8.txt`, with 131,490 bytes, 1,349 logical lines, and SHA-256 `b4ba84879b1247b9aaeb6172c6dffcb7dcc0860f8894e4651b2bc8a9fd669166`. The retained representation is confirmed, and known OCR/extraction corruption is documented without correction.[3]

The source-to-text/OCR reconciliation checklist, available question-inventory status, and answer/explanation validation requirements are now explicit. The 1,349-line count cannot be treated as a question count or completeness baseline. The absence of an answer-key or explanation inventory is an unresolved evidence gap, not evidence that answers or explanations are absent.

The authoritative `pretestnew.pdf` or equivalent, canonical source/version/locator, OCR comparison, discrepancy log, question completeness and numbering baseline, answer-key and explanation inventory, provenance, rights, track/taxonomy, and attributable review records remain open. The next allowed action is authoritative-source recovery and read-only reconciliation before owner-governed medical and assessment-quality closure.

## 6. Audit-trail update

The audit register now records the following append-only evidence-closure start events:

| Event ID | Source | Action | Evidence basis | Limitation |
|---|---|---|---|---|
| `P0-AUD-018` | Drug HTML | Defined internal metadata, available structural fields, missing clinical fields, owner-validation linkage, and internal retained-representation version ID | Locked HTML artifact and blocker-resolution report | Canonical source/version, provenance, rights, clinical/safety decisions, and approval remain open |
| `P0-AUD-019` | OSCE Atlas | Recorded 14-PNG identifiers/hashes, per-image label/accessibility requirements, and provenance/rights status | Locked package, recovery inventory, and blocker-resolution report | Canonical source/version, per-member lineage, rights, complete reviews, and approval remain open |
| `P0-AUD-020` | PreTest | Recorded OCR reconciliation checklist, question-inventory status, answer/explanation evidence gaps, and comparison requirements | Locked `UPD811-007` representation and blocker-resolution report | Authoritative source, OCR comparison, completeness, answers/explanations, provenance, rights, review, and approval remain open |

The event timestamp is the observed execution timestamp `2026-08-22T15:12:09+00:00`. These events document evidence-closure execution only. They do not record source approval, clinical validation, rights clearance, normalization, or implementation authorization.[4]

## 7. Cross-source remaining blockers

The following requirements remain open for all or applicable P0 sources:

1. Canonical source identity, version, owner/custodian, date, and original locator.
2. Provenance, transformation history, extraction lineage, recovery chain, and exact source-to-artifact linkage.
3. Rights and permitted display, educational use, adaptation, redistribution, and publication scope, including third-party material.
4. Explicit professional track and taxonomy evidence.
5. Attributable owner-governed review records with actual date/time, role/qualification, conflicts, exact artifact hash, locators, findings, limitations, and disposition.
6. Source-specific quality review: drug safety for Drug HTML; per-image clinical/visual/accessibility checks for OSCE; OCR, question, answer, explanation, and assessment-quality checks for PreTest.
7. Separate explicit source-level approval evidence before any normalization consideration.

No blocker is closed by a hash, inventory, internal version ID, checklist, requirement definition, or generated status document alone.

## 8. Current gate and next allowed action

| Control | Current state |
|---|---|
| Drug HTML | `BLOCKED_PENDING_EVIDENCE` |
| OSCE Atlas | `BLOCKED_PENDING_EVIDENCE` |
| PreTest | `BLOCKED_PENDING_EVIDENCE` |
| Source approvals | `APPROVED_SOURCES = NONE` |
| Normalization | `BLOCKED_PENDING_APPROVED_SOURCE` |
| `READY_FOR_NORMALIZATION` | `NOT_SET` |
| Source Registry approval states | `UNCHANGED` |

The next allowed phase is evidence acquisition and owner-governed review execution against exact immutable artifacts. No source content may be altered, and no downstream content record or implementation artifact may be created.

## 9. Non-actions

| Action | Result |
|---|---|
| External evidence invented | `NO` |
| Reviewer identity invented | `NO` |
| Source approval granted | `NO` |
| `READY_FOR_NORMALIZATION` set | `NO` |
| Source content modified | `NO` |
| Normalization performed | `NO` |
| Import/activation/publication performed | `NO` |
| Database/schema/application changed | `NO` |

## 10. Final status

`SEG_P0_EVIDENCE_CLOSURE_EXECUTION_COMPLETE`

This status confirms completion of the available evidence-closure documentation and progress assessment. It does not mean that any P0 source passed clinical review, rights review, provenance review, quality review, or source-level approval.

## References

[1]: file:///home/ubuntu/seg-internship-output/SEG_DRUG_HTML_CLOSURE_STATUS.md "SEG Drug HTML Closure Status"

[2]: file:///home/ubuntu/seg-internship-output/SEG_OSCE_ATLAS_CLOSURE_STATUS.md "SEG OSCE Atlas Closure Status"

[3]: file:///home/ubuntu/seg-internship-output/SEG_PRETEST_CLOSURE_STATUS.md "SEG PreTest Closure Status"

[4]: file:///home/ubuntu/seg-internship-output/SEG_P0_AUDIT_TRAIL_REGISTER.md "SEG P0 Audit Trail Register"

**Document status:** `P0_EVIDENCE_CLOSURE_PROGRESS_RECORDED_ALL_SOURCES_REMAIN_BLOCKED`
